211 related articles for article (PubMed ID: 17377984)
1. Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stents.
Moliterno DJ
Catheter Cardiovasc Interv; 2007 May; 69(6):799-800. PubMed ID: 17377984
[No Abstract] [Full Text] [Related]
2. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization.
Ortolani P; Marzocchi A; Marrozzini C; Palmerini T; Saia F; Taglieri N; Aquilina M; Baldazzi F; Silenzi S; Cooke RM; Reggiani ML; Branzi A
Catheter Cardiovasc Interv; 2007 May; 69(6):790-8. PubMed ID: 17290437
[TBL] [Abstract][Full Text] [Related]
3. Gender medicine and drug eluting coronary stents.
Kornowski R
Catheter Cardiovasc Interv; 2010 Nov; 76(6):814-6. PubMed ID: 21104730
[No Abstract] [Full Text] [Related]
4. Stent strut fracture: seeing is believing.
Carter AJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):619-20. PubMed ID: 18360854
[No Abstract] [Full Text] [Related]
5. Treating the left main bifurcation lesion: the "three stent solution".
Uretsky BF
Catheter Cardiovasc Interv; 2009 Jan; 73(1):42-3. PubMed ID: 19089935
[No Abstract] [Full Text] [Related]
6. Oral sirolimus after bare metal stent implantation: a glimpse to the future.
Mieres J
Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667
[No Abstract] [Full Text] [Related]
7. Coronary stent fracture: the hidden truth of a problem more common than stent thrombosis.
Carroll JD
Catheter Cardiovasc Interv; 2009 Jan; 73(1):88-9. PubMed ID: 19089948
[No Abstract] [Full Text] [Related]
8. A critical appraisal of the Janus carbostent.
Kornowski R
Catheter Cardiovasc Interv; 2009 Feb; 73(2):249-50. PubMed ID: 19156897
[No Abstract] [Full Text] [Related]
9. Multiple stent fractures at the site of coronary artery bypass insertion.
Hetterich H; Rieber J
Catheter Cardiovasc Interv; 2009 Jan; 73(1):84-7. PubMed ID: 19089946
[TBL] [Abstract][Full Text] [Related]
10. The artisan approach for stenting bifurcation lesions.
Colombo A; Latib A
JACC Cardiovasc Interv; 2010 Jan; 3(1):66-7. PubMed ID: 20129571
[No Abstract] [Full Text] [Related]
11. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
[TBL] [Abstract][Full Text] [Related]
13. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
Finn AV; Nakazawa G; Kolodgie FD; Virmani R
JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440
[No Abstract] [Full Text] [Related]
14. Stent fracture: an unusual cause of late restenosis after sirolimus-eluting stent placement.
Mehrle A; Skelton T; Almonacid A
Catheter Cardiovasc Interv; 2007 Jun; 69(7):988-91. PubMed ID: 17191207
[TBL] [Abstract][Full Text] [Related]
15. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
[TBL] [Abstract][Full Text] [Related]
16. A generation 2.5 drug-eluting stent?
Ellis SG
JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
[No Abstract] [Full Text] [Related]
17. A cagey proposition.
Ho YD; Lee DP
J Invasive Cardiol; 2008 Jan; 20(1):28. PubMed ID: 18174615
[No Abstract] [Full Text] [Related]
18. The process of bringing new drug-eluting stents to market will they see the light of day?
Holmes DR; Patel M
JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
[No Abstract] [Full Text] [Related]
19. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
[TBL] [Abstract][Full Text] [Related]
20. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
